Philip W. Lavori

Administrative Appointments

• Chair, Dept. of Health Research and Policy (2005 - present)
• Director, Biostatistics Shared Resource, Stanford Comprehensive Cancer Center (2004 - present)
• Acting Director, Veterans Affairs Cooperative Studies Program (National HQ) (2002 - 2004)
• Director, Veterans Affairs Cooperative Studies Program Coordinating Center, Palo Alto (1992 - 2005)

Honors and Awards

• Leadership Award, Department of Veterans Affairs Research and Development Office (2002-2004)

Professional Education

Postdoctoral Advisees

Brit Turnbull

Graduate & Fellowship Program Affiliations

• Epidemiology
• Health Research and Policy
• Infectious Diseases

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Biostatistics, clinical trials, longitudinal studies, casual inference from observational studies, genetic tissue banking, informed consent. Trial designs for dynamic (adaptive) treatment regimes, psychiatric research, cancer.

Clinical Trials

• A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft versus Host Disease Recruiting
• Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer No longer recruiting

Publications

• An {alpha}2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine Lowering Effects and Therapeutic Response of the Beta Blocker Bucindolol in Chronic Heart Failure. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. Circ Heart Fail. 2009
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. Stafford RS, Wagner TH, Lavori PW. N Engl J Med. 2009; 361 (13): 1230-3
• Sequential causal inference: application to randomized trials of adaptive treatment strategies. Dawson R, Lavori PW. Stat Med. 2008; 27 (10): 1626-45
• Adaptive treatment strategies in chronic disease. Lavori PW, Dawson R. Annu Rev Med. 2008: 59 443-53